LB-102

Phase 3Small molecule

LLB Pharmaceuticals Inc.

LB-102 is one of 41 small molecule programs targeting Schizophrenia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SchizophreniaRecruiting

SchizophreniaPhase 3

Recruiting

Competition

Competitive Landscape

174 competitors in Schizophrenia

#DrugCompanyPhaseTrials

LB-102

LLB Pharmaceuticals Inc.

Phase 3

3 2

Ozempic

Novo Nordisk

Preclinical

1 3

Resotran

Takeda

Preclinical

1 4

Inapsine

Jazz Pharmaceuticals

Preclinical

1 5

Depakote

Ibrance

Lunesta

3 8

Luvox

SSolvay Pharmaceuticals

Preclinical

1 9

Catapres

Boehringer Ingelheim

Preclinical

1 10

Rapamune

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Schizophrenia

NCT07363577

Q1 2028

Phase 2Recruiting

Bipolar I Disorder

NCT07494305

Q2 2029

Phase 3Recruiting

Schizophrenia

NCT07369154

Clinical

Trials by Indication[1]

Schizophrenia3 trials

Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

Completed·LLB Pharmaceuticals Inc.·Phase 2·NCT06179108·359 enrolled

A 52 Week, Open Label Safety and Tolerability Study of LB-102 in Adult Patients With Schizophrenia

Recruiting·LLB Pharmaceuticals Inc.·Phase 3·NCT07369154·900 enrolled

A Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate the Antipsychotic Efficacy and Safety of LB 102 in the Treatment of Adult Patients With Acute Schizophrenia

Recruiting·LLB Pharmaceuticals Inc.·Phase 3·NCT07363577·456 enrolled

ISS1 trial

Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers

Completed·LLB Pharmaceuticals Inc.·Phase 1·NCT04588129·16 enrolled

Adult1 trial

Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults

Completed·LLB Pharmaceuticals Inc.·Phase 1·NCT04187560·64 enrolled

Bipolar I Disorder1 trial

A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With Major Depressive Episodes Associated With Bipolar I Disorder

Recruiting·LLB Pharmaceuticals Inc.·Phase 2·NCT07494305·320 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for LB-102. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LB-102 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LB-102. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — LB Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: LLB Pharmaceuticals Inc.

LB-102

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2028

Q2 2029

Trials by Indication[1]

Schizophrenia3 trials

ISS1 trial

Adult1 trial

Bipolar I Disorder1 trial

References

Drug Info

Quick Facts

Related News